東海大学医学部　消化器内科　加川研究室

2024

1. Deguchi R, Ueda T, Teramura E, Arase Y, Kagawa T. Colorectal mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori eradication treatment: a report of 5 cases. J Gastrointestin Liver Dis. 2024 Sep 29;33(3):426-428. doi: 10.15403/jgld-5672. PMID: 39348583 

2. Tsuruya K, Yokoyama K, Mishima Y, Ida K, Araki T, Ieda S, Ohtsuka M, Inagaki Y, Honda A, Kagawa T, Kamiya A. Abcb4-defect cholangitis mouse model with hydrophobic bile acid composition by in vivo liver-specific gene deletion. J Lipid Res. 2024 Sep;65(9):100616. doi: 10.1016/j.jlr.2024.100616. Epub 2024 Aug 5.PMID: 39111549 

3. Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, Arase Y, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Uojima H, Hidaka H, Kusano C, Morimoto M, Maeda S. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma. Liver Int. 2024 Jun;44(6):1343-1350. doi: 10.1111/liv.15825. Epub 2024 Mar 4. PMID: 38436529

4. Chuma M, Uojima H, Toyoda H, Hiraoka A, Arase Y, Atsukawa M, Itokawa N, Okubo T, Tada T, Numata K, Morimoto M, Sugimori M, Nozaki A, Iwasaki S, Yasuda S, Koshiyama Y, Mishima Y, Tsuruya K, Tokoro C, Miura Y, Hidaka H, Kumada T, Kusano C, Kagawa T, Maeda S. Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma. Hepatol Int. 2024 Oct;18(5):1472-1485. doi: 10.1007/s12072-024-10680-8. Epub 2024 Jul 4. PMID: 38963640

5. Fujisawa M, Deguchi R, Ueda T, Teramura E, Sano M, Sato H, Arase Y, Suzuki H, Matsushima M, Kagawa T. Difficulty Confirming the Diagnosis of Amoebic Enteritis.Tokai J Exp Clin Med. 2024 Dec 20;49(4):140-143. PMID: 39572881

6. Imai J, Takashimizu S, Suzuki N, Ohshinden K, Sawamoto K, Mishima Y, Tsuruya K, Arase Y, Yamano M, Kishimoto N, Yamada C, Inoue N, Moriyama K, Baba A, Suzuki H, Kagawa T, Nishizaki Y. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD. Sci Rep. 2024 Jun 11;14(1):13411. doi: 10.1038/s41598-024-64301-3. PMID: 3886275

7. Tanaka A, Tsuji K, Komiyama Y, Tsuruya K, Kakisaka K, Tsutsui A, Ichimoto K, Ueno M, Okazaki Y, Kamimura H, Takai A, Yamashiki N, Ito T, Watanabe M, Abe M, Harada KI, Kagawa T. RECAM-J 2023-Validation and development of the Japanese version of RECAM for the diagnosis of drug-induced liver injury. Hepatol Res. 2024 Jun;54(6):503-512. doi: 10.1111/hepr.14046. Epub 2024 Apr 20. PMID: 38642343

8. Kawanishi A, Deguchi R, Ito A, Ueda T, Tsuruya K, Arase Y, Shirataki Y, Kodama T, Morimachi M, Kagawa T. Ectopic Adrenocorticotropic Hormone Syndrome due to Pancreatic Neuroendocrine Carcinoma: A Case Report. Intern Med. 2024 May 30. doi: 10.2169/internalmedicine.3672-24. Online ahead of print. PMID: 38811222

9. Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y. Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study. Hepatol Res. 2024 Dec;54(12):1215-1225. doi: 10.1111/hepr.14092. Epub 2024 Jul 11. PMID: 38990762

10. Zhang Y, Numata K, Imajo K, Uojima H, Funaoka A, Komiyama S, Ogushi K, Chuma M, Irie K, Kokubu S, Yoneda M, Kobayashi T, Hidaka H, Fukushima T, Kobayashi S, Morimoto M, Kagawa T, Hattori N, Watanabe T, Iwase S, Maeda S. Lenvatinib radiofrequency ablation sequential therapy offers survival benefits for patients with unresectable hepatocellular carcinoma at intermediate stage and the liver reserve of Child-Pugh A category: A multicenter study. Hepatol Res. 2024 Dec;54(12):1174-1192. doi: 10.1111/hepr.14089. Epub 2024 Jul 2. PMID: 38953838

11. Mishima Y, Tsuruya K, Tazawa Y, Arase Y, Hirose S, Shiraishi K, Tanaka M, Isaki S, Kitamura T, Kagawa T. An Adult Case of Benign Recurrent Intrahepatic Cholestasis Due to MYO5B Deficiency. Tokai J Exp Clin Med. 2024 Sep 20;49(3):133-136. PMID: 39182182

12. Shirataki Y, Morimachi M, Cho T, Ito A, Kawanishi A, Ito H, Izumi H, Sugiyama T, Tajiri T, Kagawa T. A Case of Pancreatic Serous Cystadenoma Penetrating Bile Duct Requiring Differentiation from Malignancy. Tokai J Exp Clin Med. 2024 Dec 20;49(4):148-152. PMID: 39572883

13. Deguchi R, Ueda T, Kaneko M, Arase Y, Tsuruya K, Kawanishi A, Kodama T, Morimachi M, Ogimi T, Kagawa T. Low-grade Appendiceal Mucinous Neoplasm with Appendiceal Reduction and Re-expansion Over a Two-year Period. Intern Med. 2024 Sep 15;63(18):2519-2523. doi: 10.2169/internalmedicine.3136-23. Epub 2024 Feb 19. PMID: 38369352

14. Morimachi M, Kakizawa M, Tsuji Y, Tazawa Y, Shirataki Y, Kawanishi A, Deguchi R, Kagawa T. Adrenal Gland Metastasis of Merkel Cell Carcinoma Diagnosed by Endoscopic Ultrasonography-guided Fine Needle Biopsy. Tokai J Exp Clin Med. 2024 Dec 20;49(4):153-158. PMID: 39572884

15. Teramura E, Deguchi R, Ueda T, Morimachi M, Sano M, Sato H, Fujisawa M, Tsuruya K, Arase Y, Kagawa T. Helicobacter pylori Eradication Therapy for Colorectal Mucosa-associated Lymphoid Tissue Lymphoma: Report of Two Cases. Tokai J Exp Clin Med. 2024 Sep 20;49(3):122-127. PMID: 39182180

16. Shomura M, Okabe H, Sakakibara M, Yaguchi N, Takahira S, Sato E, Shiraishi K, Arase Y, Tsuruya K, Hirose S, Mishima Y, Kagawa T. Immune-related adverse event detection in liver cancer patients treated with immune checkpoint inhibitors: Nationwide exploratory survey in Japan. Hepatol Res. 2024 Nov 30. doi: 10.1111/hepr.14144. Online ahead of print. PMID: 39614809

17. Shomura M, Okabe H, Sakakibara M, Sato E, Shiraishi K, Arase Y, Tsuruya K, Mishima Y, Hirose S, Kagawa T. Impact of Atezolizumab + Bevacizumab Therapy on Health-Related Quality of Life in Patients with Advanced Hepatocellular Carcinoma. Cancers (Basel). 2024 Oct 25;16(21):3610. doi: 10.3390/cancers16213610. PMID: 39518049 

18. Iwasaki S, Uojima H, Sakita S, Masuda S, Kubota K, Fujikawa T, Okubo T, Setsu T, Itokawa N, Furuichi Y, Arase Y, Tukiyama T, Fujii K, Hidaka H, Atsukawa M, Kagawa T, Kako M, Terai S, Kusano C. Esophageal Varices as an Independent Predictor of Fatal Outcomes after Balloon-Occluded Retrograde Transvenous Obliteration in Patients with Hepatic Encephalopathy. Dig Dis. 2024;42(6):583-592. doi: 10.1159/000541660. Epub 2024 Sep 30. PMID: 39348798 

​

2023

1. Fukushima T, Morimoto M, Kobayashi S, Ueno M, Uojima H, Hidaka H, Kusano C, Chuma M, Numata K, Tsuruya K, Arase Y, Kagawa T, Hattori N, Ikeda H, Watanabe T, Tanaka K, Maeda S. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. Oncologist. 2023 Jul 5;28(7):e526-e533. doi: 0.1093/oncolo/oyad090.PMID: 37023703 

2. Uojima H, Chuma M, Hidaka H, Tsuda T, Kobayashi S, Hattori N, Ogushi K, Arase Y, Take A, Sakaguchi Y, Tomoko A, Nishigori S, Wanatanbe T, Numata K, Morimoto M, Kagawa T, Kako M, Kusano C. Impact of body composition for patients with hepatocellular carcinoma who received atezolizumab plus bevacizumab therapy. Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):865-873. doi: 10.1097/MEG.0000000000002581. PMID: 37395239

3. Tanaka R, Imai J, Tsugawa H, Eap KB, Yazawa M, Kaneko M, Ohno M, Sugihara K, Kitamoto S, Nagao-Kitamoto H, Barnich N, Matsushima M, Suzuki T, Kagawa T, Nishizaki Y, Suzuki H, Kamada N, Hozumi K. Adherent-invasive E. coli - induced specific IgA limits pathobiont localization to the epithelial niche in the gut. Front Microbiol. 2023 Feb 23;14:1031997. doi: 10.3389/fmicb.2023.1031997. eCollection 2023. PMID: 36910191 

4. Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, Toyoda H, Taniai N, Yoshida H, Tanaka Y, Iwakiri K; KTK49 Liver Study Group. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study. Hepatol Res. 2023 Jan;53(1):51-60. doi: 10.1111/hepr.13840. PMID: 36136893

5. Nakamura R, Arakawa N, Tanaka Y, Uchiyama N, Sekine A, Mashimo Y, Tsuji K, Kagawa T, Sato K, Watanabe M, Aiso M, Hiasa Y, Takei Y, Ohira H, Ayada M, Tsukagoshi E, Maekawa K, Tohkin M, Saito Y, Takikawa H. Significant association between HLA-B*35:01 and onset of drug-induced liver injury caused by Kampo medicines in Japanese patients. Hepatol Res. 2023 May;53(5):440-449. doi: 10.1111/hepr.13874. PMID: 36583370

6. Tsuruya K, Koizumi J, Sekiguchi Y, Ono S, Sekiguchi T, Hara T, Mishima Y, Arase Y, Hirose S, Shiraishi K, Kagawa T. First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan. BMJ Open Gastroenterol. 2023 Apr;10(1):e001120. doi: 10.1136/bmjgast-2023-001120. PMID: 37085275.

2022

1. Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res. 2022 Mar;52(3):269-280. doi: 10.1111/hepr.13732. Epub 2021 Nov 30.PMID: 34761470

2. Ito H, Kojima S, Moriyama K, Yokota M, Shinma Y, Ito A, Kodama T, Kawanishi A, Kagawa T, Watanabe N, Suzuki T. Analysis of Comorbidity for Patients with Pancreatic Cysts in Medical Checkup Screening. Tokai J Exp Clin Med. 2022 Jul 20;47(2):60-63. PMID: 35801549

3. Shao X, Uojima H, Arai T, Ogawa Y, Setsu T, Atsukawa M, Furuichi Y, Arase Y, Horio K, Hidaka H, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Nakajima A, Terai S, Tanaka Y, Koizumi W. The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency. Dig Dis. 2022;40(5):625-634. doi: 10.1159/000521062. Epub 2021 Nov 22. PMID: 34808618 Free PMC article.

4. Imai J, Hanamura T, Kawanishi A, Ueda T, Mishima Y, Ito A, Shirataki Y, Morimachi M, Kodama T, Sato H, Kaneko M, Sano M, Teramura E, Monma M, Tsuda S, Tsuruya K, Mizukami H, Arase Y, Fujisawa M, Miyahara S, Nakamura N, Suzuki T, Matsushima M, Suzuki H, Takashimizu S, Kagawa T, Nishizaki Y. A case of breast cancer with extensive colon metastasis. DEN Open. 2022 Nov 27;3(1):e189. doi: 10.1002/deo2.189. eCollection 2023 Apr. PMID: 36447634 Free PMC article.

5. Hirose S, Tsuruya K, Shimma Y, Arase Y, Takashimizu S, Nishizaki Y, Shiraishi K, Watanabe N, Matsuzaki S, Ieda S, Kagawa T. Antiviral Therapy for Patients Chronically Infected with Hepatis C Virus at Tokai University Hospital. Tokai J Exp Clin Med. 2022 Jul 20;47(2):64-71. PMID: 35801550

6. Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Curr Oncol. 2022 May;29(5):3259-3271. doi: 10.3390/curroncol29050266. PMID: 35621656 Free PMC article.

7. Yamaji Y, Kawashima Y, Kodama T, Kawanishi A, Ito A, Ito H, Ogawa M, Kawaguchi Y, Kagawa T. Efficacy and Safety of Endoscopic Removal for Asymptomatic Common Bile Duct Stones in Comparison with Symptomatic Stones. Tokai J Exp Clin Med. 2022 Sep 20;47(3):143-148. PMID: 36073287

8. Tsuruya K, Nishizaki Y, Tatemichi M, Mishima Y, Shimma Y, Arase Y, Hirose S, Shiraishi K, Kagawa T. The prevalence and natural history of hepatic cysts examined by ultrasound: a health checkup population retrospective cohort study. Sci Rep. 2022 Jul 27;12(1):12797. doi: 10.1038/s41598-022-16875-z. PMID: 35896780 Free PMC article.

9. Nakamura R, Arakawa N, Tanaka Y, Uchiyama N, Sekine A, Mashimo Y, Tsuji K, Kagawa T, Sato K, Watanabe M, Aiso M, Hiasa Y, Takei Y, Ohira H, Ayada M, Tsukagoshi E, Maekawa K, Tohkin M, Saito Y, Takikawa H. Significant association between HLA-B*35:01 and onset of drug-induced liver injury caused by Kampo medicines in Japanese patients. Hepatol Res. 2022 Dec 30. doi: 10.1111/hepr.13874. Online ahead of print PMID: 36583370

10. Maeda K, Takikawa H, Aiso M, Tsuji K, Kagawa T, Watanabe M, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Hashimoto E, Ayada M, Ikegami T, Arakawa N, Kusuhara H, Saito Y, Sugiyama Y. Frequency of null genotypes of glutathione S-transferase M1 and T1 in Japanese patients with drug-induced liver injury. Hepatol Res. 2022 Oct;52(10):882-887. doi: 10.1111/hepr.13812. Epub 2022 Aug 5. PMID: 35834381

11. Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x. PMID: 35525913 Free PMC article.

12. Hanai T, Kawaratani H, Nagano J, Suii H, Sakamaki A, Arase Y, Nakanishi H, Kogiso T, Okubo T, Miwa T, Shimizu S, Hige S, Atsukawa M, Shimizu M, Kurosaki M, Terai S, Kagawa T, Tokushige K, Yoshiji H. Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study. Hepatol Res. 2022 Nov 25. doi: 10.1111/hepr.13860. Online ahead of print. PMID: 36433862

13. Hayama K, Atsukawa M, Tsubota A, Kondo C, Iwasa M, Hasegawa H, Takaguchi K, Tsutsui A, Uojima H, Hidaka H, Okubo H, Suzuki T, Matsuura K, Tada T, Kawabe N, Tani J, Morishita A, Ishikawa T, Arase Y, Furuichi Y, Kato K, Kawata K, Chuma M, Nozaki A, Hiraoka A, Watanabe T, Kagawa T, Toyoda H, Taniai N, Yoshida H, Tanaka Y, Iwakiri K; KTK49 Liver Study Group. Clinical outcomes of antithrombin III-based therapy for patients with portal vein thrombosis: A retrospective, multicenter study. Hepatol Res. 2023 Jan;53(1):51-60. doi: 10.1111/hepr.13840. Epub 2022 Oct 4. PMID: 36136893

​

2021

1. Arase Y, Matsumoto K, Anzai K, Tsuruya K, Sugiyama S, Yoshihara S, Hirose S, Uojima H, Hidaka H, Nakazawa T, Deguchi R, Kojima S, Takashimizu S, Shiraishi K, Shirai T, Kagawa T. Clinicopathological Features of Autoimmune Hepatitis with IgG4-Positive Plasma Cell Infiltration. Dig Dis. 2021;39(3):225-233. doi: 10.1159/000510562. Epub 2020 Jul 30. PMID: 32731217; PMCID: PMC8117379.

2. Morimachi M, Hirabayashi K, Takanashi Y, Kawanishi A, Saika T, Ueyama Y, Nakagohri T, Nakamura N, Suzuki H, Kagawa T. Low expression of DDX5 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. J Clin Pathol. 2021 Nov;74(11):741-745. doi: 10.1136/jclinpath-2020-207002. Epub 2020 Oct 23. PMID: 33097588.

3. Anzai K, Tsuruya K, Ida K, Kagawa T, Inagaki Y, Kamiya A. Kruppel-like factor 15 induces the development of mature hepatocyte-like cells from hepatoblasts. Sci Rep. 2021 Sep 17;11(1):18551. doi: 10.1038/s41598-021-97937-6. PMID: 34535735; PMCID: PMC8448749.

4. Kimura A, Kagawa T, Takei H, Maruo Y, Sakugawa H, Sasaki T, Murai T, Naritaka N, Takikawa H, Nittono H. Rotor Syndrome: Glucuronidated Bile Acidemia From Defective Reuptake by Hepatocytes.Hepatol Commun. 2020 Dec 31;5(4):629-633. doi: 10.1002/hep4.1660. PMID: 33860121; PMCID: PMC8034574.

5. Chuma M, Uojima H, Hiraoka A, Kobayashi S, Toyoda H, Tada T, Hidaka H, Iwabuchi S, Numata K, Itobayashi E, Itokawa N, Kariyama K, Ohama H, Hattori N, Hirose S, Shibata H, Tani J, Imai M, Tajiri K, Moriya S, Wada N, Iwasaki S, Fukushima T, Ueno M, Yasuda S, Atsukawa M, Nouso K, Fukunishi S, Watanabe T, Ishikawa T, Nakamura S, Morimoto M, Kagawa T, Sakamoto M, Kumada T, Maeda S. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. Hepatol Res. 2021 Feb;51(2):201-215. doi: 10.1111/hepr.13592. Epub 2021 Jan 5. PMID: 33270323.

6. Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Dig Dis. 2021;39(3):234-242. doi: 10.1159/000510692. Epub 2020 Aug 6. PMID: 32759604; PMCID: PMC8220915.

7. Tsuruya K, Anzai K, Shioyama S, Ito A, Arase Y, Hirose S, Tanaka Y, Suzuki H, Kagawa T. Case of hepatitis B virus reactivation after ibrutinib therapy in which the patient remained negative for hepatitis B surface antigens throughout the clinical course. Hepatol Res. 2021 Feb;51(2):239-244. doi: 10.1111/hepr.13575. Epub 2020 Oct 8. PMID: 32978866.

8. Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. PMID: 35071785; PMCID: PMC8762625.

9. Yamaji Y, Kawashima Y, Kodama T, Kawanishi A, Kagawa T, Mashiko T, Masuoka Y, Nakagohri T, Tomita S, Hirabayashi K. [A case of simultaneous multicentric cancer in the gallbladder duct and the common bile duct without pancreaticobiliary maljunction]. Nihon Shokakibyo Gakkai Zasshi. 2021;118(4):366-373. Japanese. doi: 10.11405/nisshoshi.118.366. PMID: 33840718.

10. Naitoh I, Kamisawa T, Tanaka A, Nakazawa T, Kubota K, Takikawa H, Unno M, Masamune A, Kawa S, Nakamura S, Okazaki K; collaborators. Clinical characteristics of immunoglobulin IgG4-related sclerosing cholangitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort. Dig Liver Dis. 2021 Oct;53(10):1308-1314. doi: 10.1016/j.dld.2021.02.009. Epub 2021 Mar 2. PMID: 33664004.

 

2020

1. Nakano Y, Kamiya A, Sumiyoshi H, Tsuruya K, Kagawa T, Inagaki Y. A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice. Hepatology. 2020 Apr;71(4):1437-1452. doi: 10.1002/hep.30965. PMID: 31549421.

2. Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H, Tanaka Y, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W. Usefulness of autotaxin for the complications of liver cirrhosis. World J Gastroenterol. 2020 Jan 7;26(1):97-108. doi: 10.3748/wjg.v26.i1.97. PMID: 31933517; PMCID: PMC6952300.

3. Arase Y, Tsuruya K, Hirose S, Ogiwara N, Yokota M, Anzai K, Deguchi R, Shiraishi K, Shirai T, Kagawa T. Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases. Hepatology. 2020 Feb;71(2):757-759. doi: 10.1002/hep.30904. PMID: 31429969; PMCID: PMC7028030.

4. Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2020 Jan 26;12(2):293. doi: 10.3390/cancers12020293. PMID: 31991869; PMCID: PMC7073176.

5. Yamamoto Y, Kakizaki M, Shimizu T, Carreras J, Chiba T, Chamoto K, Kagawa T, Aoki T, Nakamura N, Ando K, Kotani A. PD-L1 is induced on the hepatocyte surface via CKLF-like MARVEL transmembrane domain-containing protein 6 up-regulation by the anti-HBV drug Entecavir. Int Immunol. 2020 Jul 28;32(8):519-531. doi: 10.1093/intimm/dxaa018. PMID: 32219331.

6. Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S, Kobayashi S, Hattori N, Ogushi K, Morimoto M, Kagawa T, Tanaka K, Kako M, Koizumi W. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020 Apr;9(2):193-206. doi: 10.1159/000504604. PMID: 32399433; PMCID: PMC7206580.

​

2019

1. Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T. Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Clin Drug Investig. 2019 Jul;39(7):631-641. doi: 10.1007/s40261-019-00785-6. PMID: 30993553; PMCID: PMC6593121.

2. Tamori A, Inoue K, Kagawa T, Takaguchi K, Nouso K, Iwasaki Y, Minami M, Hai H, Enomoto M, Kawada N. Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res. 2019 Dec;49(12):1365-1373. doi: 10.1111/hepr.13410. PMID: 31323165.

3. Hirose S, Yamaji Y, Tsuruya K, Ogawa Y, Miyaoka M, Kagawa T. Rapid Regression of B-Cell Non-Hodgkin's Lymphoma after Eradication of Hepatitis C Virus by Direct Antiviral Agents. Case Rep Gastroenterol. 2019 Jul 26;13(2):336-341. doi: 10.1159/000501546. PMID: 31543755; PMCID: PMC6738223.

4. Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res. 2019 Jan;49(1):105-110. doi: 10.1111/hepr.13288. PMID: 30565816.

5. Tsuruya K, Koizumi J, Sekiguchi T, Hara T, Sekiguchi Y, Anzai K, Arase Y, Hirose S, Kagawa T. Successful Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices Using Foam Sclerosant Followed by Glue Embolization of Gastrorenal Shunt via the Brachial Vein Approach in a Severely Obese Patient. Ann Vasc Dis. 2019 Dec 25;12(4):562-565. doi: 10.3400/avd.cr.19-00084. PMID: 31942222; PMCID: PMC6957899.

6. Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig. 2019 Jan;39(1):45-54. doi: 10.1007/s40261-018-0714-5. PMID: 30284699; PMCID: PMC6510826.

 

2018

1. Kakizaki M, Yamamoto Y, Yabuta S, Kurosaki N, Kagawa T, Kotani A. The immunological function of extracellular vesicles in hepatitis B virus-infected hepatocytes. PLoS One. 2018 Dec 31;13(12):e0205886. doi: 10.1371/journal.pone.0205886. PMID: 30596665; PMCID: PMC6312312.

2. Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271. PMID: 30581275; PMCID: PMC6295839.

3. Kamiya A, Chikada H, Ida K, Ando E, Tsuruya K, Kagawa T, Inagaki Y. An in vitro model of polycystic liver disease using genome-edited human inducible pluripotent stem cells. Stem Cell Res. 2018 Oct;32:17-24. doi: 10.1016/j.scr.2018.08.018. PMID: 30172093.

4. Fujii Y, Koizumi J, Hara T, Sekiguchi T, Ono S, Mine T, Kagawa T, Hirose S, Tsuruya K, Anzai K, d'Othee BJ, Imai Y. Utility of a 3D Roadmap During Balloon- occluded Retrograde Transvenous Obliteration for Gastric Varices. Tokai J Exp Clin Med. 2018 Apr 20;43(1):14-18. PMID: 29637534.

5. Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg- interferon sequential therapy. J Gastroenterol. 2018 Feb;53(2):247-257. doi: 10.1007/s00535-017-1360-z. PMID: 28634723.

 

2017

1. Kagawa T, Adachi Y, Hashimoto N, Mitsui H, Ohashi T, Yoneda M, Hasegawa I, Hirose S, Tsuruya K, Anzai K, Mine T. Loss of organic anion transporting polypeptide 1B3 function causes marked delay in indocyanine green clearance without any clinical symptoms. Hepatology. 2017 Mar;65(3):1065-1068. doi: 10.1002/hep.28950. PMID: 27863442; PMCID: PMC5324621.

 

2016

1. Anzai K, Chikada H, Tsuruya K, Ida K, Kagawa T, Inagaki Y, Mine T, Kamiya A. Foetal hepatic progenitor cells assume a cholangiocytic cell phenotype during two-dimensional pre-culture. Sci Rep. 2016 Jun 23;6:28283. doi: 10.1038/srep28283. PMID: 27335264; PMCID: PMC4917868.

2. Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol. 2016 Mar 17;16:38. doi: 10.1186/s12876-016-0454-z. PMID: 26987437; PMCID: PMC4794926.

3. Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, Tsuruya K, Takahira S, Mine T. Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment. BMC Cancer. 2016 Nov 11;16(1):878. doi: 10.1186/s12885-016-2908-7. PMID: 27835949; PMCID: PMC5106792.

 

2015

1. Kagawa T, Hirose S, Arase Y, Oka A, Anzai K, Tsuruya K, Shiraishi K, Orii R, Ieda S, Nakazawa T, Tomita K, Hokari R, Miura S, Ebinuma H, Saito H, Kitamura T, Horie Y, Okuse C, Wasada M, Inoko H, Tohkin M, Saito Y, Maekawa K, Takikawa H, Mine T. No contribution of the ABCB11 p.444A polymorphism in Japanese patients with drug-induced cholestasis. Drug Metab Dispos. 2015 May;43(5):691-7. doi: 10.1124/dmd.114.061325. PMID: 25713208.

2. Kagawa T, Oka A, Kobayashi Y, Hiasa Y, Kitamura T, Sakugawa H, Adachi Y, Anzai K, Tsuruya K, Arase Y, Hirose S, Shiraishi K, Shiina T, Sato T, Wang T, Tanaka M, Hayashi H, Kawabe N, Robinson PN, Zemojtel T, Mine T. Recessive inheritance of population-specific intronic LINE-1 insertion causes a rotor syndrome phenotype. Hum Mutat. 2015 Mar;36(3):327-32. doi: 10.1002/humu.22745. PMID: 25546334.

3. Itou C, Koizumi J, Hashimoto T, Myojin K, Kagawa T, Mine T, Imai Y. Balloon- Occluded Retrograde Transvenous Obliteration for the Treatment of Gastric Varices: Polidocanol Foam Versus Liquid Ethanolamine Oleate. AJR Am J Roentgenol. 2015 Sep;205(3):659-66. doi: 10.2214/AJR.14.13389. PMID: 26295655.

4. Tsuruya K, Chikada H, Ida K, Anzai K, Kagawa T, Inagaki Y, Mine T, Kamiya A. A Paracrine Mechanism Accelerating Expansion of Human Induced Pluripotent Stem Cell-Derived Hepatic Progenitor-Like Cells. Stem Cells Dev. 2015 Jul 15;24(14):1691-702. doi: 10.1089/scd.2014.0479. PMID: 25808356; PMCID: PMC4499795.

 

2014

1. Itou C, Koizumi J, Hashimoto T, Myojin K, Kagawa T, Mine T, Imai Y. Foam sclerotherapy for a symptomatic hepatic cyst: a preliminary report. Cardiovasc Intervent Radiol. 2014 Jun;37(3):800-4. doi: 10.1007/s00270-013-0761-5. PMID: 24170168; PMCID: PMC4024151.

2. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, Mine T. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014 Sep 27;6(9):670-6. doi: 10.4254/wjh.v6.i9.670. PMID: 25276283; PMCID: PMC4179146.

3. Kagawa T, Orii R, Hirose S, Arase Y, Shiraishi K, Mizutani A, Tsukamoto H, Mine T. Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells. J Gastroenterol. 2014 May;49(5):890-9. doi: 10.1007/s00535-013-0833-y. PMID: 23722250.

 

2013

1. Koizumi J, Itou C, Wray R, Myojin K, Hashimoto T, Nagata Y, Yamamuro H, Tsuji T, Ichikawa T, Shiraishi K, Kagawa T, Mine T, Watanabe N, Matsumae M, Janne d'Othée B. Partial splenic embolisation using n-butyl cyanoacrylate: intraprocedural evaluation by magnetic resonance imaging. Eur Radiol. 2013 May;23(5):1429-42. doi: 10.1007/s00330-012-2711-z. PMID: 23160664.

2. Kojima S, Watanabe N, Takashimizu S, Kagawa T, Shiraishi K, Koizumi J, Hirabayashi K, Ohkubo T, Kamiguchi H, Tsuda M, Mine T. Senescent case of cholesterol ester storage disease that progressed to liver cirrhosis with a novel mutation (N250H) of lysosomal acid lipase gene. Hepatol Res. 2013 Dec;43(12):1361-7. doi: 10.1111/hepr.12087. PMID: 23675960.

3. Kagawa T, Kojima S, Shiraishi K, Hirose S, Arase Y, Takashimizu S, Watanabe N, Nagata N, Numata M, Shiozawa H, Nishizaki Y, Toki M, Sugita T, Nomura K, Sakaguchi T, Atsukawa K, Tajima H, Tei Y, Inomoto T, Mine T. Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. Hepatol Res. 2013 Sep;43(9):925-32. doi: 10.1111/hepr.12046. PMID: 23356876.

 

2012

1. Koizumi J, Hashimoto T, Myojin K, Itou C, Kagawa T, Nishibe T, Janne d'Othée B. Balloon-occluded retrograde transvenous obliteration of gastric varices: use of CT-guided foam sclerotherapy to optimize technique. AJR Am J Roentgenol. 2012 Jul;199(1):200-7. doi: 10.2214/AJR.11.7002. PMID: 22733913.

2. Koizumi J, Hashimoto T, Myojin K, Itou C, Hara T, Sekiguchi T, Ichikawa T, Imai Y, Kagawa T, Nagata N, Watanabe N, Mine T, Nishibe T, Saguchi T, Janne d'Othée B. Carbon dioxide (CO2) vs iodinated contrast digital subtraction angiography during balloon-occluded retrograde transvenous obliteration (BRTO) using foam sclerosant for gastric varices. J Vasc Interv Radiol. 2012 Nov;23(11):1453-1459.e1. doi: 10.1016/j.jvir.2012.08.004. PMID: 23101917.

3. Miyata M, Hata T, Yamakawa H, Kagawa T, Yoshinari K, Yamazoe Y. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):41-7. doi: 10.1016/j.jsbmb.2012.04.008. PMID: 22561792.

4. Mizukami H, Kagawa T, Arase Y, Nakahara F, Tsuruya K, Anzai K, Hirose S, Shiraishi K, Shomura M, Koizumi J, Tobita K, Mine T. Complete response after short-term sorafenib treatment in a patient with lymph node metastasis of hepatocellular carcinoma. Case Rep Oncol. 2012 May;5(2):380-4. doi: 10.1159/000341259. PMID: 23525021; PMCID: PMC3409511.

5. Kagawa T, Kojima S, Shiraishi K, Takashimizu S, Nagata N, Shiozawa H, Nishizaki Y, Ikeda A, Tei Y, Atsukawa K, Kamochi J, Wasada M, Numata M, Arase Y, Hirose S, Yamada T, Hata Y, Watanabe N, Morizane T, Mine T. Weight-based high- and low-dose ribavirin in combination with peginterferon α-2b therapy for genotype 2 chronic hepatitis C: A randomized trial. Hepatol Res. 2012 Apr;42(4):351-8. doi: 10.1111/j.1872-034X.2011.00944.x. PMID: 22176474.

6. Hirose S, Kagawa T, Shiraishi K, Nagata N, Okada K, Tajima T, Mukai M, Sekido Y, Mine T. Type 1 gastric cancer presenting as protein-losing gastroenteropathy and ball-valve syndrome. Dig Endosc. 2012 Jan;24(1):55. doi: 10.1111/j.1443-1661.2011.01164.x. PMID: 22211419.

 

2011

1. Takashimizu S, Kojima SI, Nagata J, Nishizaki Y, Kagawa T, Shiraishi K, Mine T, Kaneko JI, Kokudo N, Watanabe N. Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C. Clin J Gastroenterol. 2011 Jun;4(3):167-173. doi: 10.1007/s12328-011-0216-y. PMID: 26189349.

2. Takashimizu S, Kojima S, Nishizaki Y, Kagawa T, Shiraishi K, Mine T, Watanabe N. Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats. Implications for endothelin-1 in portal hypertension. Tokai J Exp Clin Med. 2011 Jul 20;36(2):37-43. PMID: 21769771.

 

2010

1. Koizumi J, Hashimoto T, Myojin K, Fukushima T, Ichikawa T, Kagawa T, Kojima S, Watanabe N, Mine T, Nishibe T, Janne d'Othée B. C-arm CT-guided foam sclerotherapy for the treatment of gastric varices. J Vasc Interv Radiol. 2010 Oct;21(10):1583-7. doi: 10.1016/j.jvir.2010.05.029. PMID: 20801674.

2. Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T; Tokai RFA Study Group. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010 Aug 1;116(15):3638-44. doi: 10.1002/cncr.25142. PMID: 20564097.

3. Numata M, Kagawa T, Kojima S, Hirose S, Nagata N, Shiraishi K, Watanabe N, Shiozawa H, Nishizaki Y, Motegi S, Takashimizu S, Kamochi J, Wasada M, Ohno T, Tei Y, Nakano A, Yamada T, Atsukawa K, Watanabe T, Mine T. Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis C. Hepat Res Treat. 2010;2010:702748. doi: 10.1155/2010/702748. PMID: 21188199; PMCID: PMC3003990.

 

2008

1. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G58-67. doi: 10.1152/ajpgi.00367.2007. PMID: 17947449.

2. Kagawa T, Shiozawa H, Kojima S, Takashimizu S, Nagata N, Numata M, Morino F, Nishizaki Y, Mochizuki K, Watanabe N, Watanabe T, Matsuzaki S, Mine T. Eight- week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C. Hepatol Res. 2008 Mar;38(3):259-66. doi: 10.1111/j.1872-034X.2007.00260.x. PMID: 17825059.

 

2007

1. Watanabe N, Kojima S, Takashimizu S, Nishizaki Y, Kagawa T, Phillips MJ. Initial site of bile regurgitation following extrahepatic biliary obstruction in living rats. J Gastroenterol Hepatol. 2007 Nov;22(11):1983-92. doi: 10.1111/j.1440-1746.2006.04623.x. PMID: 17914981.

2. Watanabe N, Takashimizu S, Nishizaki Y, Kojima S, Kagawa T, Matsuzaki S. An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J Gastroenterol. 2007 Sep;42(9):775-82. doi: 10.1007/s00535-007-2093-1. PMID: 17876548.

3. Kagawa T, Watanabe N, Mochizuki K, Numari A, Ikeno Y, Itoh J, Tanaka H, Arias IM, Mine T. Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2008 Jan;294(1):G58-67. doi: 10.1152/ajpgi.00367.2007. PMID: 17947449.

4. Mochizuki K, Kagawa T, Numari A, Harris MJ, Itoh J, Watanabe N, Mine T, Arias IM. Two N-linked glycans are required to maintain the transport activity of the bile salt export pump (ABCB11) in MDCK II cells. Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G818-28. doi: 10.1152/ajpgi.00415.2006. PMID: 17082223.

5. Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T. Altered cell motility behaviour and reorganization of contractile proteins after primary monolayer cultures of isolated hepatocytes. Tokai J Exp Clin Med. 2007 Mar 20;32(1):34-41. PMID: 21319055.

6. Takashimizu S, Watanabe N, Kojima S, Kagawa T, Mine T, Myojin K, Koizumi J. Efficacy of balloon-occluded retrograde transvenous obliteration (B-RTO) performed in a patient with primary biliary cirrhosis with severe recurrent hepatic encephalopathy due to splenorenal shunt. Tokai J Exp Clin Med. 2007 Jul 20;32(2):70-4. PMID: 21319062.

7. Watanabe N, Takashimizu S, Kojima S, Kagawa T, Nishizaki Y, Mine T, Matsuzaki S. Clinical and pathological features of a prolonged type of acute intrahepatic cholestasis. Hepatol Res. 2007 Aug;37(8):598-607. doi: 10.1111/j.1872-034X.2007.00115.x. PMID: 17517076.

​

2006

1. Watanabe N, Kagawa T, Kojima S, Takashimizu S, Nagata N, Nishizaki Y, Mine T. Taurolithocholate impairs bile canalicular motility and canalicular bile secretion in isolated rat hepatocyte couplets. World J Gastroenterol. 2006 Sep 7;12(33):5320-5. doi: 10.3748/wjg.v12.i33.5320. PMID: 16981261; PMCID: PMC4088198.

2. Watanabe N, Takashimizu S, Shiraishi K, Kagawa T, Nishizaki Y, Mine T, Akatsuka A, Selmi C, Gershwin ME. Primary biliary cirrhosis with multinucleated hepatocellular giant cells: implications for pathogenesis of primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2006 Sep;18(9):1023-7. doi: 10.1097/01.meg.0000230082.60921.be. PMID: 16894319.

3. Takahashi H, Kagawa T, Kobayashi K, Hirabayashi H, Yui M, Begum L, Mine T, Takagi S, Saheki T, Shinohara Y. A case of adult-onset type II citrullinemia-- deterioration of clinical course after infusion of hyperosmotic and high sugar solutions. Med Sci Monit. 2006 Feb;12(2):CS13-5. PMID: 16449956.

4. Nishizaki Y, Morizane T, Kojima S, Sakuma K, Koyama A, Shiozawa H, Morino F, Aoki J, Matsuzaki S, Kagawa T, Watanabe N, Mine T. Predictive factors for the response to lamivudine in HBV-infected patients with chronic hepatitis and cirrhosis. Tokai J Exp Clin Med. 2006 Sep 20;31(3):121-4. PMID: 21302238.

5. Watanabe N, Nishizaki Y, Kojima S, Takashimizu S, Nagata N, Kagawa T, Shiraishi K, Mine T, Matsuzaki S. Clinical significance of serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic liver disease. Tokai J Exp Clin Med. 2006 Sep 20;31(3):96-101. PMID: 21302232.

 

2004

1. Kagawa T, Watanabe N, Kanouda H, Takayama I, Shiba T, Kanai T, Kawazoe K, Takashimizu S, Kumaki N, Shimamura K, Matsuzaki S, Mine T. Fatal liver failure due to reactivation of lamivudine-resistant HBV mutant. World J Gastroenterol. 2004 Jun 1;10(11):1686-7. doi: 10.3748/wjg.v10.i11.1686. PMID: 15162553; PMCID: PMC4572782.

2. Harris MJ, Kagawa T, Dawson PA, Arias IM. Taurocholate transport by hepatic and intestinal bile acid transporters is independent of FIC1 overexpression in Madin-Darby canine kidney cells. J Gastroenterol Hepatol. 2004 Jul;19(7):819-25. doi: 10.1111/j.1440-1746.2004.03347.x. PMID: 15209631.

3. Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima S, Nagata N, Nakano A, Nishizaki Y, Shiraishi K, Itakura M, Watanabe N, Mine T, Matsuzaki S. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol. 2004 Mar 1;10(5):733-6. doi: 10.3748/wjg.v10.i5.733. PMID: 14991949; PMCID: PMC4716920.

 

2002

1. Kagawa T, Varticovski L, Sai Y, Arias IM. Mechanism by which cAMP activates PI3-kinase and increases bile acid secretion in WIF-B9 cells. Am J Physiol Cell Physiol. 2002 Dec;283(6):C1655-66. doi: 10.1152/ajpcell.00041.2002. PMID: 12388099.

​

2000

1. Hosoi K, Hagihara M, Kagawa T, Watanabe N, Matsuzaki S. The serum soluble HLA-DR antigens as a predictive marker of the response to interferon-alpha treatment in patients with chronic hepatitis C. Tokai J Exp Clin Med. 2000 Oct;25(3):117-24. PMID: 11368209.

 

1999

1. Kagawa T, Sato M, Hosoi K, Uchiyama J, Nishizaki Y, Watanabe N, Inagaki Y, Kimura M, Matsuzaki S. Absence of R1066X mutation in six Japanese patients with Dubin-Johnson syndrome. Biochem Mol Biol Int. 1999 Apr;47(4):639-44. doi: 10.1080/15216549900201693. PMID: 10319416.

2. Hagihara M, Hosoi K, Kagawa T, Gansuvd B, Munkhbat B, Shimura T, Watanabe N, Matsuzaki S, Tsuji K. Serum soluble HLA-DR antigens in autoimmune hepatitis. Autoimmunity. 1999 Oct;31(2):85-93. doi: 10.3109/08916939908994051. PMID: 10680746.

 

1998

1. Kagawa T, Watanabe N, Sato M, Nakano A, Nishizaki Y, Hosoi K, Takashimizu S, Uchiyama J, Kimura M, Matsuzaki S. Differential expression of multidrug resistance (mdr) and canalicular multispecific organic anion transporter (cMOAT) genes following extrahepatic biliary obstruction in rats. Biochem Mol Biol Int. 1998 Mar;44(3):443-52. doi: 10.1080/15216549800201462. PMID: 9556204.

2. Kagawa T, Hosoi K, Takashimizu S, Kawazoe K, Mochizuki K, Wasada M, Nagata N, Uchiyama J, Nakano A, Nishizaki Y, Watanabe N, Matsuzaki S. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C. Am J Gastroenterol. 1998 Feb;93(2):192-6. doi: 10.1111/j.1572-0241.1998.00192.x. PMID: 9468240.

 

1997

1. Hagihara M, Shimura T, Takebe K, Munkhbat B, Hosoi K, Kagawa T, Watanabe N, Matsuzaki S, Yamamoto K, Sato K, Tsuji K. Serum concentrations of soluble HLA- class I and CD8 forms in patients with viral hepatic disorders. J Gastroenterol. 1997 Jun;32(3):338-43. doi: 10.1007/BF02934490. PMID: 9213247.